| Segment Information |
3.
Segment Information
The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s
CODM and included in research and development costs for the three and six months and June 30, 2026 and 2025.
Schedule
of Information by Segment
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended | | |
Six Months Ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Clinical and related oversight costs | |
$ | 15,018 | | |
$ | 11,601 | | |
$ | 324,812 | | |
$ | 27,470 | |
| Preclinical research focused on development of additional novel anti-cancer compounds | |
| 47,077 | | |
| 27,592 | | |
| 70,659 | | |
| 70,362 | |
| Compound maintenance | |
| - | | |
| 20,265 | | |
| - | | |
| 53,083 | |
| Regulatory service costs | |
| 155 | | |
| 1,190 | | |
| 155 | | |
| 1,190 | |
| Total research and development costs | |
$ | 62,250 | | |
$ | 60,648 | | |
$ | 395,626 | | |
$ | 152,105 | |
The
following table presents a summary of research and development costs for the three and six months ended June 30, 2026 and 2025 based
on the respective geographical regions where such costs were incurred.
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended | | |
Six Months Ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| United States | |
$ | 40,119 | | |
$ | 41,928 | | |
$ | 79,092 | | |
$ | 100,499 | |
| Spain | |
| 22,131 | | |
| 18,720 | | |
| 316,534 | | |
| 51,606 | |
| Total | |
$ | 62,250 | | |
$ | 60,648 | | |
$ | 395,626 | | |
$ | 152,105 | |
| Total research and development costs | |
$ | 62,250 | | |
$ | 60,648 | | |
$ | 395,626 | | |
$ | 152,105 | |
The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s
CODM and included in general and administrative costs for the three and six months ended June 30, 2026 and 2025.
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended | | |
Six Months Ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Stock-based compensation | |
$ | 622,614 | | |
$ | 240,499 | | |
$ | 704,790 | | |
$ | 312,737 | |
| Quarterly board fees | |
| 29,258 | | |
| 27,500 | | |
| (27,775 | ) | |
| 55,000 | |
| Patent and licensing legal and filing fees costs | |
| 30,785 | | |
| 17,303 | | |
| 65,817 | | |
| 73,386 | |
| Marketing and public relations | |
| 139,000 | | |
| - | | |
| 370,900 | | |
| - | |
| Accounting and bookkeeping services | |
| 172,975 | | |
| 72,337 | | |
| 559,681 | | |
| 167,356 | |
| Audit and legal | |
| 102,169 | | |
| 84,474 | | |
| 167,775 | | |
| 165,911 | |
| Consulting fees | |
| 103,047 | | |
| 29,811 | | |
| 275,744 | | |
| 57,315 | |
| Insurance expense | |
| 64,387 | | |
| 64,277 | | |
| 128,774 | | |
| 128,553 | |
| Investment banking | |
| - | | |
| 19,740 | | |
| 250,000 | | |
| 48,600 | |
| Payroll | |
| 226,842 | | |
| 104,948 | | |
| 444,769 | | |
| 195,711 | |
| Lease | |
| 152,306 | | |
| - | | |
| 297,671 | | |
| - | |
| Other costs and expenses, net | |
| 644,287 | | |
| 53,272 | | |
| 703,555 | | |
| 125,075 | |
| Total general and administrative costs | |
$ | 2,287,670 | | |
$ | 714,161 | | |
$ | 3,941,701 | | |
$ | 1,329,644 | |
|